These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Nanocalcium-deficient hydroxyapatite-poly (e-caprolactone)-polyethylene glycol-poly (e-caprolactone) composite scaffolds.
    Author: Wang Z, Li M, Yu B, Cao L, Yang Q, Su J.
    Journal: Int J Nanomedicine; 2012; 7():3123-31. PubMed ID: 22848159.
    Abstract:
    A bioactive composite of nano calcium-deficient apatite (n-CDAP) with an atom molar ratio of calcium to phosphate (Ca/P) of 1.50 and poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) (PCL-PEG-PCL) was synthesized, and a composite scaffold was fabricated. The composite scaffolds with 40 wt% n-CDAP contained well interconnected macropores around 400 μm, and exhibited a porosity of 75%. The weight-loss ratio of the n-CDAP/PCL-PEG-PCL was significantly greater than nano hydroxyapatite (n-HA, Ca/P = 1.67)/PCL-PEG-PCL composite scaffolds during soaking into phosphate-buffered saline (pH 7.4) for 70 days, indicating that n-CDAP-based composite had good degradability compared with n-HA. The viability ratio of MG-63 cells was significantly higher on n-CDAP than n-HA-based composite scaffolds at 3 and 5 days. In addition, the alkaline phosphatase activity of the MG-63 cells cultured on n-CDAP was higher than n-HA-based composite scaffolds at 7 days. Histological evaluation showed that the introduction of n-CDAP into PCL-PEG-PCL enhanced the efficiency of new bone formation when the composite scaffolds were implanted into rabbit bone defects. The results suggested that the n-CDAP-based composite exhibits good biocompatibility, biodegradation, and osteogenesis in vivo.
    [Abstract] [Full Text] [Related] [New Search]